Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic therapy is unclear. Here we examine recent evidence indicating that combining percutaneous hepatic perfusion with immune-checkpoint inhibitors might improve patient outcomes, compare it with data from other trials and highlight key questions around patient selection, sequencing and mechanisms that will shape future strategies.
Access to this article via Institution of Civil Engineers Library is not available. van den Hoek, L.
et al. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol. 27 , 372–382 (2026).
Zager, J. S.
et al. Efficacy and safety of the melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study.
Ann. Surg.
Oncol. 31 , 5340–5351 (2024).
Bagge, R. O.
et al. Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial).
J. Clin.
Oncol. 41 , 3042–3050 (2023).
Olofsson Bagge, R. et al.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 29 Apr 2026.
The item focuses on Synergistic integration of regional and systemic therapies in uveal melanoma.
Review the original article for the full source wording and details.